SBIR/STTR Research Award
Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease
Award amount
$2,165,664Program and phase
SBIR · Phase IIAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- GABAeron, Inc.
- Proposal award date
- 2019-12-15
- Contract end date
- 2021-11-30
- UEI
- RVDNEZQNYZN3
- Solicitation number
- PAS18-187
- Topic code
- NIA
Research abstract
PROJECT NARRATIVE
The goals of this proposal are to develop and optimize compounds targeting apolipoprotein (apo) E4–induced
GABAergic interneuron impairment as a novel therapeutic approach for Alzheimer’s disease and to test the
efficacy of the lead GABAergic interneuron protectors in apoE4-knock-in mice and human induced pluripotent
stem cell–derived neurons carrying the apoE4 allele.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4
- Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease
- Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
4 SBIR/STTR records share this UEI (2018–2020). Reported award amounts total $4,731,346. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services